Similarly, HCQ has been shown to reduce the extent of thrombosis in an animal model of injury-induced thrombosis in APS, reverse aPL-induced platelet activation and to protect the EC annexin A5 anticoagulant shield from disruption by aPL54. This evidence concerns the gene FASLG and Venous thrombosis.